Continuous Administration of Basic Fibroblast Growth Factor (FGF-2) Accelerates Bone Induction on Rat Calvaria— An Application of a New Drug Delivery System

Abstract

Some studies have shown that locally applied basic fibroblast growth factor (FGF-2) enhances bone regeneration at a fracture site, while others have not been in agreement. We developed a new continuous FGF-2 delivery system designed to accelerate cytokine-induced new bone formation. A subperiosteal pocket was surgically formed in 36 eight-week-old male Wistar rats. The rats were administered 0, 1, 10, or 100 ng of FGF-2 contained in a collagen minipellet, mixed with allogeneic demineralized bone matrix in a dome-shaped Millipore® filter and then placed into the pocket. New bone formation in the dome was evaluated at 2, 4, and 8 wks after placement. Soft x-ray radiographs disclosed an apparently larger radiopaque region in the 1-ng group at 4 wks compared with those in the other groups. Morphometrical analysis revealed that the new bone area in the 1-g group was significantly larger than that in the 0-g group (p < 0.01). In the 100-ng FGF-2 group, new bone formation seemed suppressed. We concluded that continuous slow administration of a small amount of FGF-2 accelerates bone-derived osteogenic cytokine-induced new bone formation.

Keywords

basic fibroblast growth factor new drug delivery system bone induction.

Get full access to this article

View all access options for this article.

References

Aspenberg P. , Thorngren KG , Lohmander LS (1991). Dose-dependent stimulation of bone induction by basic fibroblast growth factor in rats. Acta Orthop Scand 62 :481-484.

Baylink DJ , Finkelman RD , Mohan S. (1993). Growth factors to stimulate bone formation. J Bone Miner Res 8(Suppl 2) :S565-S572.

Bland YS , Critchlow MA , Ashhurst DE (1995). Exogenous fibroblast growth factors-1 and -2 do not accelerate fracture healing in the rabbit. Acta Orthop Scand 66:543-548.

Bolander ME (1992). Regulation of fracture repair by growth factors . Proc Soc Exp Biol Med 200:165-170.

Fujioka K. , Takada Y. , Sato S. , Miyata T. (1995a). Long-acting delivery system of interferon: IFN minipellet. J Control Release 33:317-323.

Fujioka K. , Takada Y. , Sato S. , Miyata T. (1995b). Novel delivery system for proteins using collagen as a carrier material: the minipellet. J Control Release 33:307-315.

Globus RK , Patterson Buckendahl P. , Gospodarowicz D. (1988). Regulation of bovine bone cell proliferation by fibroblast growth factor and transforming growth factor beta. Endocrinology 123:98-105.

Gospodarowicz D. (1990). Fibroblast growth factor. Chemical structure and biologic function. Clin Orthop 257:231-248.

Gospodarowicz D. , Moran JS (1974). Stimulation of division of sparse and confluent 3T3 cell populations by a fibroblast growth factor, dexamethasone, and insulin . Proc Natl Acad Sci USA 71:4584-4588.

10.

Hiraki Y. , Inoue H. , Shigeno C. , Sanma Y. , Bentz H. , Rosen DM , et al. (1991). Bone morphogenetic proteins (BMP-2 and BMP-3) promote growth and expression of the differentiated phenotype of rabbit chondrocytes and osteoblastic MC3T3-El cells in vitro. J Bone Miner Res 6:1373-1385.

11.

Hirasawa T. , Sano A. , Fujioka K. , Inoue K. , Miyata K. , Nakano M. , et al. (1997). Biodegradability of minipellet, a new drug formulation using atelocollagen as a drug carrier material, in the rhesus monkey. Biomed Res 18:149-159.

12.

Hollinger J. (1993). Factors for osseous repair and delivery. Part I. J Craniofac Surg 4:102-108.

13.

Kato Y. , Iwamoto M. (1990). Fibroblast growth factor is an inhibitor of chondrocyte terminal differentiation. J Biol Chem 265:5903-5909.

14.

Kawaguchi H. , Kurokawa T. , Hanada K. , Hiyama Y. , Tamura M. , Ogata E. , et al. (1994). Stimulation of fracture repair by recombinant human basic fibroblast growth factor in normal and streptozotocin-diabetic rats. Endocrinology 135:774-781.

15.

Mazue G. , Bertolero F. , Garofano L. , Brughera M. , Carminati P. (1992). Experience with the preclinical assessment of basic fibroblast growth factor (bFGF). Toxicol Lett 64-65(Spec No):329-338.

16.

Mazue G. , Newman AJ , Scampini G. , Della Torre P. , Hard GC , Iatropoulos MJ , et al. (1993). The histopathology of kidney changes in rats and monkeys following intravenous administration of massive doses of FCE 26184, human basic fibroblast growth factor. Toxicol Pathol 21:490-501.

17.

Mohan S. , Baylink DJ (1991). Bone growth factors. Clin Orthop 263:30-48.

18.

Neigel JM , Ruzicka PO (1996). Use of demineralized bone implants in orbital and craniofacial reconstruction and a review of the literature. Ophthalmol Plast Reconstr Surg 12:108-120.

19.

Reddi AH , Huggins C. (1972). Biochemical sequences in the transformation of normal fibroblasts in adolescent rats. Proc Natl Acad Sci 69:1601-1605.

20.

Rudkin GH , Miller TA (1996). Growth factors in surgery. Plast Reconstr Surg 97:469-476.

21.

Wang JS ( 1996). Basic fibroblast growth factor for stimulation of bone formation in osteoinductive or conductive implants. Acta Orthop Scand 269(Suppl):1-33.

22.

Wang JS , Aspenberg P. (1994). Basic fibroblast growth factor increases allograft incorporation. Bone chamber study in rats. Acta Orthop Scand 65:27-31.

23.

Yamada K. , Tabata Y. , Yamamoto K. , Miyamoto S. , Nagata I. , Kikuchi H. , et al. (1997). Potential efficacy of basic fibroblast growth factor incorporated in biodegradable hydrogels for skull bone regeneration . J Neurosurg 86:871-875.